Mirtazapine Sandoz

Mirtazapine, the active ingredient in Mirtazapine Sandoz, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adults. GNH USA supplies Mirtazapine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders and related symptom clusters. - Major depressive disorder: alleviates depressive mood, improves sleep and appetite. - Depressive episodes with insomnia: promotes better sleep quality. - Depression with anxiety symptoms: reduces anxiety and tension associated with depressive states.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (rash, angioedema) - Suicidal thoughts or behavior, especially early in therapy - Serotonin syndrome when combined with other serotonergic agents - Hepatotoxicity (rare) - Unusual bleeding or clotting disorders

Before initiating therapy, consider the following safety measures. - Monitor weight: watch for rapid weight gain or loss. - Assess hepatic function: adjust if liver disease is present. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to minimise withdrawal. - Screen for suicidal ideation: especially during the first weeks of treatment. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased serotonin syndrome risk. - CNS depressants (benzodiazepines, alcohol): additive sedation and respiratory depression. - Potent CYP1A2 inhibitors: may raise mirtazapine plasma levels. - Antihistamines: heightened anticholinergic effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (fluoxetine, paroxetine): may increase exposure. - CYP3A4 inhibitors (ketoconazole, erythromycin): moderate increase in levels. - Antihypertensives: possible additive hypotensive effect. - Lithium: monitor for neurotoxicity. - Anticholinergic drugs: may exacerbate dry mouth and constipation.